< Back to Newsroom

WebAlert: MultiCell Technologies Presenting during SmallCapInsights.com's ''Emerging Growth Forum'' Starting Today at 12 Noon ET Webcast Highlighting Auriga Laboratories, MultiCell Technologies, Titan Global Holdings and Peace Arch Entertainment SAN DIEGO--(BUSINESS WIRE)--MultiCell Technologies, Inc. (OTCBB:MCET - News), along with SmallCapInsights.com, a leading investment newsletter committed to discovering tomorrow's smallcap breakthroughs, will host an "Emerging Growth Forum" via webcast, today at 12 noon Eastern, featuring on-camera presentations by Chief Executive Officers, Philip S. Pesin of Auriga Laboratories, Dr. Stephen Chan of MultiCell Technologies, Bryan Chance of Titan Global Holdings, and Peace Arch Entertainment President John Flock. This live over-the-Internet video presentation employs a fast-moving, highly informative format designed specifically for the smallcap and microcap investor. Investment commentator Dr. John Faessel, publisher of the widely read online financial news source, Jag Notes, will deliver the Forum's keynote address. Dr. Faessel, a well-known authority on smallcap investment strategies, will discuss high-growth investment opportunities. To participate, please register online as explained below. The webcast will last approximately 20 minutes. WHAT: "Emerging Growth Form" from SmallCapInisights.com WHEN: Today, November 22, 2006, at 12 noon Eastern HOW: Visit http://smallcapinsights.com five to ten minutes prior to the start time and log on COST: The forum is free of charge. For those unable to view the initial webcast, the Forum will be archived for replay at http://smallcapinsights.com. About MultiCell Technologies, Inc. MultiCell Technologies, Inc. is an integrated biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology. MultiCell's drug development program is focused on modulation of the immune system. MultiCell's therapeutic pipeline includes drug candidates some of which are in various advanced stages of human clinical trials. These therapies include: MCT-125 for the treatment of chronic fatigue in MS patients. MCT-125 completed a Phase II clinical trial and demonstrated significant efficacy in reducing chronic fatigue in MS patients. There is no drug specifically approved for the treatment of chronic fatigue in MS patients anywhere in the world. MCT-175 for the treatment of relapsing-remitting MS. MCT-175, in preclinical development for the treatment of relapsing-remitting MS, targets disease specific autoaggressive T-cells that destroy the myelin sheath of nerve cells. MCT-175 successfully ameliorated the disease in animal models. MCT-275 for the treatment of type-1 diabetes. MCT-275, in preclinical development, targets disease-specific autoaggressive T-cells that destroy insulin producing cells in the pancreas. MCT-275 completely reversed the type-1 diabetic phenotype and prolonged life in animal models. MCT-465 in an adjuvant therapy for the treatment of virus infection and cancer. MCT-465 in preclinical studies successfully reduced pulmonary influenza virus levels 1,000-fold in animal models, and has demonstrated effectiveness in reducing virus levels of HIV and HCV in animal models. MCT-465 in preclinical studies successfully eliminated certain types of tumors in animal models. The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics. For more information about MultiCell Technologies, please visit http://www.multicelltech.com. About SmallCapInsights.com The editors and publishers of SmallCapInsights.com have decades of direct experience both in the markets and in the newsletter genre as well as being avid students of the sector. The Companies we illuminate and represent are those we feel have the best chance of enhancing portfolio returns as we take them from initial profile to ongoing in-depth coverage. We aren't married to any space within the smallcap sector, just to those ideas and strategies that will make our opinions and observations a relevant starting point to your complete and ongoing due diligence. The good, the bad and the bizarre -and hopefully profitable--will populate our pieces. Our readers will first and foremost be our priority. Every article will include a detailed disclaimer. We are not analysts, but rather view our picks as an investor might: questioning, commenting and delivering our best opinions, be they pro or con. As well, in each piece we will highlight a technical opinion, which, though it can never be definitive, will serve to give readers a quick snapshot of our current T/A thoughts. For more information, visit http://www.smallcapinsights.com. Compensation Disclosures Editorial is provided by SmallcapInsights.com (``Smallcap'') to provide readers with information on publicly traded companies which have retained Smallcap to provide editorial commentary. Smallcap receives compensation for those services from the company, which consists of cash and/or securities of the company. Factual information is obtained from public filings and other sources deemed to be reliable; however, Smallcap takes no responsibility for verifying the accuracy of such information and makes no representation that such information is accurate or complete. Further, Smallcap and its employees and affiliates may own, or may purchase and sell, securities of the companies profiled. Smallcap undertakes no obligation to inform readers about the ownership or trading activities of it or its employees or affiliates in the securities of the profiled companies. As of September 11, 2006, SmallcapInsights.com receives an aggregate of US$21,500 for six months of editorial coverage. Forward-Looking Statements Certain of the statements in this release may be considered forward-looking statements. Smallcap makes no representation and provides no assurance or guaranty that such forward-looking statements will be prove to be accurate. Statements of opinion and belief are those of the authors and/or editors of this release, and are based solely upon the information possessed by such authors and/or editors; no inference should be drawn that such authors or editors have any special or greater knowledge about the companies profiled or any particular expertise in the industries or markets in which the profiled companies compete. The reader should verify all claims and complete his own due diligence before investing in any securities of profiled companies. Neither Smallcap nor anyone involved in the publication of this editorial is a registered investment adviser or broker/dealer. Smallcap makes no recommendation that the purchase of securities of companies profiled in this editorial is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. An investor in such securities should be prepared and able to bear a loss of his or her entire investment. Nothing in this editorial should be construed as an offer or solicitation to buy or sell any securities of any profiled company. Contact: MultiCell Technologies, Inc. Dr. Stephen Chang MCETInvestor@MultiCelltech.com or Trilogy Capital Partners (Financial Communications) Paul Karon, 800-592-6067 paul@trilogy-capital.com Source: Business Wire (Wednesday November 22, 6:30 am ET)